Connect® MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
This Disease Registry will collect data on patient characteristics, treatment patterns and
clinical outcomes. The objective is to describe how newly diagnosed MDS or AML patients are
treated; and to build a knowledge base regarding the effectiveness and safety of front-line
and subsequent treatment regimens in both community and academic settings. Enrolled
patients will receive treatment and evaluations for MDS or AML according to the standard of
care and routine clinical practice at each study site. All treatments that patients receive
for MDS or AML will be recorded, including initial treatment and any subsequent therapy.
Data on treatment outcomes, including response rates as measured by the treating physician,
evidence of progression, survival, and patient-reported outcomes will be collected quarterly
on the electronic CRF.
Observational Model: Cohort, Time Perspective: Prospective
Describe demographics, baseline characteristics and clinical outcomes of the patients with LR or HR MDS, MDS risk not determined, and AML.
Up to 8 years
Oleg Zernovak, M.D.
United States: Institutional Review Board
Connect® MDS/AML Registry